

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 0 574 255 B1**

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention  
of the grant of the patent:  
05.03.1997 Bulletin 1997/10

(51) Int. Cl.<sup>6</sup>: **C07D 417/12**, **C07C 211/56**,  
**A61K 31/54**, **A61K 31/19**

(21) Application number: **93304496.8**

(22) Date of filing: **10.06.1993**

(54) **New derivatives of non-steroidal anti-inflammatory, analgesic and/or antipyretic substances, their use and pharmaceutical formulations containing them**

Derivate von nicht-steroidalen entzündungshemmenden analgetischen und/oder antipyretischen Arzneimitteln, ihre Verwendung und diese enthaltende pharmazeutische Zubereitungen

Dérivés de substances anti-inflammatoires, analgésiques et/ou anti-pyretiques non-stéroïdiens, leur application et formulations pharmaceutiques qui les contiennent

(84) Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL  
PT SE**

(30) Priority: **11.06.1992 GB 9212450**

(43) Date of publication of application:  
**15.12.1993 Bulletin 1993/50**

(73) Proprietor: **INDENA S.p.A.**  
**20139 Milano (IT)**

(72) Inventor: **Bombardelli, Ezio**  
**I-20141 Milan (IT)**

(74) Representative: **Ritter, Stephen David et al**  
**Mathys & Squire**  
**100 Grays Inn Road**  
**London WC1X 8AL (GB)**

(56) References cited:

<b>EP-A- 0 123 520</b>	<b>EP-A- 0 152 379</b>
<b>EP-A- 0 249 561</b>	<b>EP-A- 0 260 241</b>
<b>DE-A- 3 346 526</b>	<b>GB-A- 2 201 089</b>

- **PATENT ABSTRACTS OF JAPAN (14544) 4**  
**December 1990 ( TAISHO PHARMACEUTICAL**  
**CO., LTD ) 17 September 1990**
- **CHEMICAL ABSTRACTS**, vol. 108, no. 2, 11  
January 1988, Columbus, Ohio, US; abstract no.  
11133v, T. NISHIHATA 'Simple formulation of  
sustained-release tablets of sodium diclofenac  
and examination in humans.' page 325 ;
- **CHEMICAL ABSTRACTS**, vol. 107, no. 6, 10  
August 1987, Columbus, Ohio, US; abstract no.  
46308n, 'Suppositories containing analgesics,  
antipyretics, or inflammation inhibitors.' page  
421 ;
- **CHEMICAL AND PHARMACEUTICAL BULLETIN**.  
vol. 35, no. 7, 1987, TOKYO JP pages 3049 - 3053  
Y. HIROTANI ET AL. 'Preparation of controlled-  
release granules of sodium diclofenac.'

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 0 574 255 B1**

## Description

The present invention relates to new derivatives of non-steroidal anti-inflammatory, analgesic and/or antipyretic substances, to processes for their production and to novel pharmaceutical compositions and dosage forms containing them.

More specifically, the present invention relates to the therapeutic use of new salts of non-steroidal anti-inflammatory analgesic and/or antipyretic substances that are useful in the treatment of superficial or deep inflammatory conditions, such as erythemas of various origins, inflammation of the joints or inflammation of bacterial origin. In the present specification, the abbreviation "NSA" will be used to denote the expression "non-steroidal anti-inflammatory, analgesic and/or antipyretic substance".

Typical NSAs in widespread use include acetylsalicylic acid (aspirin), 4-(2-methylpropyl)benzenacetic acid (ibufenac),  $\alpha$ -methyl-4-(2-methylpropyl)benzenacetic acid (ibuprofen) and 1-(4-chlorobenzoyl)-5-methoxy-1H-indole-3-acetic acid (indomethacin).

However these NSAs suffer the disadvantage that when administered orally, they tend to cause irritation of the stomach, even leading to bleeding and stomach ulcers.

A further disadvantage of available NSAs is that they generally are highly hydrophilic and consequently are not readily converted into dosage forms which are adapted to partition into the lipid phase. Also available dosage forms are not readily adapted for transcutaneous administration nor for formulation into convenient sustained release forms.

In an attempt to avoid these disadvantages a class of NSAs has been developed, which contain a basic nitrogen atom or atoms, which may be present for example as primary, secondary or tertiary amino groups, or other nitrogen-containing groups, such as amido groups. Examples include 2-((2,6-dichlorophenyl)amino)-benzene-acetic acid (diclofenac) and (4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide (piroxicam).

EP-A-0 249 561 describes compositions comprising a nonsteroidal anti-inflammatory drug and a glycolipid, for example a glycosphingolipid or a galactolipid. The preparation of liposomes is particularly referred. According to the specification, lipids that may be used include glycolipids such as glycosphingolipids and galactolipids such as digalactosyl diglyceride (DGDG) or monogalactosyl diglyceride (MGDG) and DGDG and/or MGDG in combination with phospholipids such as phosphatidylcholine, phosphatidylserine, phosphatidylinositol, or phosphatidylethanolamine and their derivatives and sterol or tocopherol monoesters of diacids, such as cholesterol hemisuccinate and tocopherol hemisuccinate, respectively.

EP-A-0 152 379 relates to a process for the manufacture of compositions containing unilamellar liposomes by homogeneously mixing a phospholipid and an amphiphatic compound having biological activity, dispersing the resulting homogeneous mixture in an aqueous phase and neutralising the resulting dispersion.

We have now developed a novel class of NSA derivatives which avoid disadvantages of prior art compounds and compositions.

Thus according to the invention there are provided salts of non-steroidal anti-inflammatory, analgesic and/or antipyretic substances (NSAs) and phosphatidic acids, said salts having the formula



wherein

NSA represents a cation derived from said non-steroidal anti-inflammatory analgesic and/or antipyretic substance,

PA represents an anion derived from a phosphatidic acid or a mixture of anions derived from different phosphatidic acids, and

x and y are in a stoichiometric ratio of 1:1.

Generally, basic NSAs are used to form salts according to the invention e.g. NSAs containing one or more basic nitrogen atom, for example primary, secondary or tertiary amino groups. Thus, in examples of the novel salts of the invention, the non-steroidal anti-inflammatory, analgesic and/or antipyretic substance is preferably diclofenac (2-((2,6-dichlorophenyl)amino)benzene-acetic acid) or piroxicam (4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide).

The term "phosphatidic acid" as used herein, can represent a compound having the formula.



wherein  $\text{R}_1$  and  $\text{R}_2$ , which may be the same or different each represents a  $\text{C}_{10-24}$  alkyl group, a  $\text{C}_{10-24}$  alkenyl group, or a  $\text{C}_{10-24}$  alkadienyl group. Said groups may be represented respectively by the formulae  $\text{C}_n\text{H}_{2n+1}$ ,  $\text{C}_n\text{H}_{2n-1}$  or  $\text{C}_n\text{H}_{2n-3}$  wherein  $n$  is from 10 to 24.

Preferably,  $n$  is from 15 to 24, most preferably 15 or 17.

In more specific terms, the present invention relates to new salts of basic NSAs with phosphatidic acids that exhibit increased bioavailability when administered by mouth, rectally, transcutaneously or transepidermally. For reasons explained below, the transcutaneous and transepidermal routes are the administration routes of choice for the new substances according to the invention.

The new salts of the invention are highly lipophilic and have a high level of bioavailability when administered by mouth or transcutaneously or transepidermally. The new salts are of particular value, when incorporated in adhesive plasters or suitable gels or appropriate pharmaceutical forms, for the treatment of localised inflammatory processes where an appropriate concentration of the drug can rapidly reduce the disease concerned.

The products are suitable for use in the fields of dermatology, orthopaedics and internal medicine; they are also of wide application in the systemic treatment of painful and febrile conditions of inflammatory origin.

According to a further aspect of the invention there are provided pharmaceutical compositions comprising a salt according to the invention, preferably one of the preferred salts referred to above, and a pharmaceutically acceptable excipient.

The salts according to the invention are especially well adapted for formulation into sustained release pharmaceutical dosage forms capable of releasing their pharmacologically active substance (i.e. the non-steroidal anti-inflammatory, analgesic and/or antipyretic substance) over a period of time and in particular to release the pharmaceutically active substance trans-cutaneously.

For this purpose, the sustained release forms are preferably in the form of a cutaneous patch, plaster or bandage.

The salts of the invention may be prepared by a process comprising salification of (a) basic NSAs and (b) one or more phosphatidic acids, each of said reactants (a) and (b) being in free form or in the form of a salt-forming derivative.

The salification is preferably carried out in a solution for both reactants.

The solvent is preferably selected from halogenated hydrocarbons, ketones, ethers and mixtures thereof.

Suitable phosphatidic acids for use as salifying agents are natural or synthetic phosphatidic acids. In general these possess acyl chains (which may be the same or different and may be saturated or unsaturated) linked via an ester bond to the oxygen atoms of glycerol. Included are natural phosphatidic acids comprising compounds having different fatty acids present in the ratio corresponding to the natural ratio in the compounds from the plant or animal tissue from which they originate.

The salification is normally carried out in aprotic solvents, generally starting from NSAs in the form of the free base or salified with weak acids and from free phosphatidic acid(s). Alternatively, the salification may be carried out using a trans-salification procedure (or double decomposition reaction) in which a salt of an NSA with an anion  $\text{X}^-$  is reacted with a salt of a phosphatidic acid with a cation  $\text{Y}^+$ , wherein the salt  $\text{Y}^+ \cdot \text{X}^-$  is essentially insoluble in reaction medium. An example is the reaction of a hydrochlorate of an NSA with a sodium or potassium salt of phosphatidic acid(s).

The salts of the NSAs thus obtained are highly soluble in non-protic solvents, from which they can be isolated by concentration and if necessary evaporation to dryness or by insolubilisation in non-solvents such as hexane or petroleum ether.

The salts may normally be obtained by reacting the reagents in molar proportions (1M:1M). Salification is generally complete when complete solubility of the reagents in the chosen solvent is achieved.

When treated with water, the novel salts of the invention can adopt a micellar form and distribute themselves quantitatively in non-miscible lipophilic organic solvents. The salts of the invention are believed to acquire their lipophilic character from the ability of the acyl chains to wrap themselves around the most polar central nucleus i.e. the region of the molecule constituted by the basic NSAs, with the result that they can form a liposomal microdispersion in aqueous

media.

It has surprisingly been found that when the novel salts of the invention are administered in the form of gelled aqueous microdispersions (lipogels), or incorporated in controlled release plasters applied to various parts of the body, they have considerable therapeutic advantages over the traditional dosage forms of NSAs. It has been shown that in these dosage forms the new salts according to the invention have a different level of bioavailability, with an attendant positive effects on their activity.

It has also been found (and this constitutes one of the most important aspects of the invention) that when the lipophilic salts of the NSAs are applied topically, e.g. in controlled-release formulations, especially ones in liposomal or pseudoliposomal form, they can interact rapidly with the cell structures and diffuse rapidly through the tissues where they can easily gain access to the desired site of action.

One of the aims of the invention concerns in particular the topical application of these new substances for the treatment of inflammatory changes attributable to rheumatoid arthritis or degenerative joint diseases of similar origin.

These new salts can be applied to the above sites in dosages of between 10 and 2000mg given as one or more doses per day.

It is clear that if consistent results are to be obtained in chronic inflammatory diseases there must be a constant supply of the drug to the target organ in quantities sufficient to produce the required effect. This may be achieved using salts according to the invention.

Controlled-release transcutaneous pharmaceutical forms have proved suitable for the administration of the new salts according to the invention since they enable the drug to be directed to the target organ with minimal transfer to sites where the drug is not required or is poorly tolerated (e.g. the stomach).

Controlled-release plasters have proved to be particularly effective for this purpose.

Liposomal forms of the same salt applied in the form of lipogels, with or without the presence of conventional phospholipids, have also proved effective. The plaster form has also proved extremely practical for long-term use. The salts according to the invention can also be incorporated and administered in other conventional forms such as oily solutions, gels, ointments, creams, lotions, tablets, capsules, suppositories, and occlusive dressings. It is one particular advantage of the salts of the invention that they salts can be dissolved in unsaturated vegetable oils with a vasokinetic action such as the esters of ximeninic acid or of eicosapentenoic acids, etc. These oils in which the salts according to the present invention are freely soluble, can constitute an appropriate vehicle that is capable of increasing the permeation of the tissues by the products. Solutions of the new anti-inflammatory salts in this oily matrix can be used in the treatment of psoriasis and many forms of dermatitis in which the inflammatory process is associated with changes in the microcirculation.

The salts according to the invention can be applied in the form of aqueous microdispersions or lipogels or in conventional gels and emulsions to large areas of the body such as the upper and lower limbs to treat deep inflammation.

The new salts according to the invention produce better results than the NSAs themselves under these conditions because they are better distributed in the surface tissue and remain present at the site of action for longer periods of time.

The following pharmacological data illustrates the use of the novel salts of the invention and their advantages over available NSAs.

In a first series of experiments the reduction of croton oil-induced oedema in the mouse was studied, using the method described by Bri P. *et al.*, **Agents and Actions** 17, 347 (1985).

The results appear in the following Table I:

Table I

Reduction in croton II-Induced oedema in the mouse after the administration of salts of dipalmitoylphosphatidic acid with diclofenac		
Substances	Dose ( $\mu$ M per animal)	% reduction in oedema
Controls	--	--
Phosphatic acid (PhA)	0.3 $\mu$ M	12.5
	0.5 $\mu$ M	32.6
Diclofenac (DicF)	0.1 $\mu$ M	--
	0.3 $\mu$ M	18.2
	1 $\mu$ M	27.2*
DicF-PhA salt	0.3 $\mu$ M	49.2*
	0.5 $\mu$ M	65.1*
	1 $\mu$ M	84.2*

\*  $p < 0.05$  Student t test

In a second series of experiments the effects in rheumatoid arthritis induced in the rat by an injection of bacterial toxin (Freund adjuvant) into the paw. In this test the rat's paw was treated topically by immersing it in an aqueous microdispersion of the salt, so as to simulate topical treatment in man.

The substances were applied topically in the form of microdispersions in water; the arthritis was induced and the measurements taken by the method described by Winter and Nuss, 1966.

Table II

Antiarthritic activity of the salt of dipalmitoylphosphatidic acid with piroxicam in the rat			
Substances	No. of rats	Dose (mg per animal)	Reduction in volume of paw
Piroxicam (PiC)	12	20	14%
	12	40	22%*
	11	60	28%*
Phosphatidic Acid (PhA)	12	100	--
PiC-PhA salt	12	60	35%*
	12	120	62%*
	10	180	73%*

\*  $p < 0.05$  Student's t test

#### Example I - Preparation of the salt of hydrogenated soya phosphatidic acid with 2-((2,6-dichlorophenyl)-amino)-benzeneacetic acid.

2.97 g 2-((2,6-dichlorophenyl)amino)benzeneacetic acid are dissolved in 15 ml methylene chloride with stirring and 7 g hydrogenated soya phosphatidic acid (natural ratio of fatty acids) with a mean molecular weight, determined by acid-

base titration, of 698 are added.

When the reagents have dissolved completely, the solution in methylene chloride is evaporated to dryness under vacuum at a temperature not exceeding 40°C until the solvent has been completely eliminated. The residue is dispersed in n-hexane at 5°C and filtered.

This yields 9.5 g of an amorphous white solid with an unknown melting point and a  $[\alpha]_D$  (conc 0.5% in  $\text{CHCl}_3$ ) = +6.82)  $^{31}\text{P}$ -NMR 0.45, 0.03 ppm.

**Example II - Preparation of the salt of hydrogenated soya phosphatidic acid with 4-hydroxy 2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide**

3.3 g 4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide are dissolved in 15 ml methylene chloride with stirring and 7 g hydrogenated soya phosphatidic acid (natural ratio of fatty acids) with a mean molecular weight, determined by acid-base titration, of 698 are added.

When the reagents have dissolved completely, the solution in methylene chloride is evaporated to dryness under vacuum at a temperature not exceeding 40°C until the solvent has been completely eliminated. The residue is dispersed in n-hexane at 5°C and filtered.

This yields 10 g of an amorphous white solid with an unknown melting point and a  $[\alpha]_D$  (conc 0.5% in  $\text{CHCl}_3$ ) = +5.77)  $^{31}\text{P}$ -NMR 0.62, 0.25 ppm.

**Example III - Oily lotion containing the phosphatide of 4-hydroxy 2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide**


0.5 g of the phosphatide of 4-hydroxy- 2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide are dissolved in 50 ml ethylximeninate; this pharmaceutical form is applied directly to the skin and is useful in the treatment of psoriasis and joint diseases.

**Example IV - Lipogel containing the phosphatide of 4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide**

To prepare 100 g lipogel, 1 g 4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide phosphatide is mixed with 15 g pure soya phosphatidyl-choline and the whole is dispersed in 83 g water; when micro-dispersion has taken place, 0.5 g carboxymethyl-cellulose is added as a thickener. The lipogel is useful in the treatment of atopic dermatitis and as a coadjuvant in rheumatoid arthritis.

**Claims**

1. A salt of a non-steroidal anti-inflammatory, analgesic and/or antipyretic substance (NSA) and a phosphatidic acid, said salt having the formula



wherein

NSA represents a cation derived from said non-steroidal anti-inflammatory analgesic and/or antipyretic substance,

PA represents an anion derived from a phosphatidic acid or a mixture of anions derived from different phosphatidic acids, and

x and y are in a stoichiometric ratio of 1:1.

2. A salt according to Claim 1 wherein the NSA is 2-((2,6-dichloro-phenyl)amino)benzene-acetic acid (diclofenac) or 4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide (piroxicam).

3. A salt according to Claim 1 or Claim 2 where PA is a phosphatidic acid having the formula





15 wherein  $\text{R}_1$  and  $\text{R}_2$ , which may be the same or different each represents a  $\text{C}_{10-24}$  alkyl group, a  $\text{C}_{10-24}$  alkenyl group, or a  $\text{C}_{10-24}$  alkadienyl group represented respectively by the formulae  $\text{C}_n\text{H}_{2n+1}$ ,  $\text{C}_n\text{H}_{2n-1}$  or  $\text{C}_n\text{H}_{2n-3}$  wherein  $n$  is from 10 to 24.

- 20 4. A salt according to Claim 3, wherein  $n$  is from 15 to 24.
5. A salt according to Claim 4 wherein  $n$  is 15 or 17.
- 25 6. A salt according to any of Claims 1 to 5 wherein NSA is a cation derived from 2-((2,6-dichloro-phenyl)amino)benzene-acetic acid (diclofenac) or 4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide (piroxicam).
7. A method for producing a salt as claimed in any preceding claim which comprises reacting a basic NSA with a phosphatidic acid, said reaction being carried out in a solution for both reactants.
- 30 8. A method according to Claim 7 wherein the solvent is selected from halogenated hydrocarbons, ketones, ethers and mixtures thereof.
9. A pharmaceutical composition comprising a salt according to any of Claims 1 to 6 and a pharmaceutically acceptable excipient.
- 35 10. A pharmaceutical composition according to Claim 9 wherein said excipient comprises an unsaturated vegetable oil.
11. A sustained release pharmaceutical dosage form capable of releasing an NSA over a period of time, characterised in that the pharmaceutically active substance is a salt as claimed in any of Claims 1 to 6.
- 40 12. A sustained release pharmaceutical dosage form as claimed in Claim 11, adapted to release the pharmaceutically active substance trans-cutaneously.
13. A sustained release pharmaceutical dosage form according to Claim 12 in the form of a cutaneous patch, plaster or bandage.
- 45 14. The use of a salt of an NSA and a phosphatidic acid as claimed in Claim 1 in the manufacture of a pharmaceutical composition for use in the treatment of inflammatory conditions of the skin and joints.

# 50 Patentansprüche

1. Salz eines nicht-steroiden, entzündungshemmenden, analgetischen und/oder antipyretischen Stoffes (NSA) und einer Phosphatidinsäure, wobei das Salz die Formel aufweist




worin NSA ein Kation darstellt, das von dem nicht-steroiden, entzündungshemmenden, analgetischen und/oder anti-pyretischen Stoff abgeleitet ist, PA ein Anion darstellt, das von einer Phosphatidinsäure abgeleitet ist oder ein Gemisch von Anionen darstellt, das von verschiedenen Phosphatidinsäuren abgeleitet ist, und  $x$  und  $y$  in

einem stöchiometrischen Verhältnis von 1:1 vorliegen.

2. Salz nach Anspruch 1, worin der NSA 2-((2,6-Dichlorphenyl)amino)benzolessigsäure (Diclofenac) oder 4-Hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazin-3-carboxamid-1, 1-dioxid (Piroxicam) ist.

3. Salz nach Anspruch 1 oder Anspruch 2, wobei PA eine Phosphatidinsäure der Formel ist



worin  $\text{R}^1$  und  $\text{R}^2$ , die gleich oder verschieden sein können, jeweils eine  $\text{C}_{10-24}$ -Alkylgruppe, eine  $\text{C}_{10-24}$ -Alkenylgruppe oder eine  $\text{C}_{10-24}$ -Alkadienylgruppe, wiedergegeben durch die Formeln  $\text{C}_n\text{H}_{2n+1}$ ,  $\text{C}_n\text{H}_{2n-1}$  bzw.  $\text{C}_n\text{H}_{2n-3}$ , worin n 10 bis 24 bedeutet, wiedergeben.

4. Salz nach Anspruch 3, worin n 15 bis 24 ist.

5. Salz nach Anspruch 4, worin n 15 oder 17 ist.

6. Salz nach einem der Ansprüche 1 bis 5, wobei NSA ein Kation, abgeleitet von 2-((2,6-Dichlorphenyl)amino)benzolessigsäure (Diclofenac) oder 4-Hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazin-3-carboxamid-1,1-dioxid (Piroxicam) ist.

7. Verfahren zur Herstellung eines Salzes nach einem vorangehenden Anspruch, umfassend Umsetzen eines basischen NSA mit einer Phosphatidinsäure, wobei die Umsetzung in einer Lösung für beide Reaktanten ausgeführt wird.

8. Verfahren nach Anspruch 7, wobei das Lösungsmittel ausgewählt ist aus halogenierten Kohlenwasserstoffen, Ketonen, Ethern und Gemischen davon.

9. Pharmazeutische Zusammensetzung, umfassend ein Salz nach einem der Ansprüche 1 bis 6 und einen pharmazeutisch verträglichen Exzipienten.

10. Pharmazeutische Zusammensetzung nach Anspruch 9, wobei der Exzipient ein ungesättigtes Pflanzenöl umfaßt.

11. Pharmazeutische Dosierungsform mit inhaltender Freigabe, die einen NSA über einen Zeitraum freigeben kann, dadurch gekennzeichnet, daß der pharmazeutische Wirkstoff ein Salz nach einem der Ansprüche 1 bis 6 ist.

12. Pharmazeutische Dosierungsform mit inhaltender Freigabe nach Anspruch 11, ausgelegt zur transkutanen Freigabe eines pharmazeutischen Wirkstoffs.

13. Pharmazeutische Dosierungsform mit inhaltender Freigabe nach Anspruch 12 in Form eines kutanen Patch, Pflasters oder Verbands.

14. Verwendung eines Salzes eines NSA und einer Phosphatidinsäure nach Anspruch 1 bei der Herstellung einer pharmazeutischen Zusammensetzung zur Verwendung bei der Behandlung entzündlicher Zustände der Haut und Gelenke.

## R v ndications

1. Sel de substance anti-inflammatoire, analgésique, et/ou antipyrétique non stéroïdienne (NSA) et d'un acide phosphatidique ayant la formule :



dans laquelle :

- 5 - NSA représente un cation dérivé de ladite substance anti-inflammatoire, analgésique, et/ou antipyrétique non stéroïdienne ,  
 - PA représente un anion dérivé d'un acide phosphatidique, ou un mélange d'anions dérivés de différents acides phosphatidiques, et  
 - x et y sont dans un ratio stoechiométrique de 1/1.

10


2. Sel selon la revendication 1, dans lequel NSA représente le 2-[(2,6-dichlorophényl)amino]benzène-acétique acide (diclofénac) ou le 4-hydroxy-2-méthyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxyde (piroxicam).

15

3. Sel selon la revendication 1, ou la revendication 2, dans lequel PA représente un acide phosphatidique ayant la formule :

20

25



30

dans laquelle  $\text{R}^1$  et  $\text{R}^2$  qui peuvent être identiques ou différents, représentent chacun un groupe alkyle  $\text{C}_{10-24}$ , un groupe alkényle  $\text{C}_{10-24}$ , ou un groupe alkadiényle  $\text{C}_{10-24}$ , représentés respectivement par les formules  $\text{C}_n\text{H}_{2n+1}$ ,  $\text{C}_n\text{H}_{2n-1}$  ou  $\text{C}_n\text{H}_{2n-3}$  dans lesquelles n est compris entre 10 et 24.

35

4. Sel selon la revendication 3, dans lequel n est compris entre 15 et 24.

5. Sel selon la revendication 4, dans lequel n est égal à 15 ou à 17.

40

6. Sel selon l'une quelconque des revendications 1 à 5, dans lequel NSA est un cation dérivé du 2-[(2,6-dichlorophényl)amino]benzène-acétique acide (diclofénac) ou du 4-hydroxy-2-méthyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxyde (piroxicam).

45

7. Méthode de production d'un sel selon l'une quelconque des revendications précédentes, qui comprend la réaction d'un NSA basique avec un acide phosphatidique, ladite réaction étant effectuée dans une solution des deux réactants.

50

8. Méthode selon la revendication 7, dans laquelle le solvant est choisi parmi les hydrocarbures halogénés, les cétones, les éthers, et les mélanges de ceux-ci.

9. Composition pharmaceutique comprenant un sel selon l'une quelconque des revendications 1 à 6, et un excipient pharmaceutiquement acceptable.

10. Composition pharmaceutique selon la revendication 9, dans laquelle ledit excipient comprend une huile végétale non saturée.

55

11. Forme pharmaceutique à libération prolongée, capable de libérer un NSA sur une certaine période de temps, caractérisée en ce que la substance pharmaceutiquement active, est un sel selon l'une quelconque des revendications 1 à 6.

12. Forme pharmaceutique à libération prolongée selon la revendication 11, adaptée à la libération de la substance

pharmaceutiquement active, par voie transcutanée.

13. Forme pharmaceutique à libération prolongée selon la revendication 12, présentée sous la forme d'un timbre, emplâtre, ou bandage cutané.

5

14. Utilisation d'un sel d'un NSA et d'un acide phosphatidique selon la revendication 1, dans la fabrication d'une composition pharmaceutique pour l'emploi dans le traitement des états inflammatoires de la peau, et des articulations.

10

15

20

25

30

35

40

45

50

55